Key Summary of Published Article

A *Grammastola spatulata* Mechanotoxin-4 (GsMTx4)-Sensitive Cation Channel Mediates Increased Cation Permeability in Human Hereditary Spherocytosis of Multiple Genetic Etiologies



Background

- Hereditary spherocytosis (HS) is a rare hemolytic anemia caused by mutations in the genes *ANK1*, *SLC4A1*, *SPTB*, *SPTA1*, and *EPB42*. These genes encode proteins that function in membranes of red blood cells.¹
- Some of these mutations are associated with increased cation permeability in red blood cells, which is also seen in HS patients.^{1,2}
- Previous reports on how mutations affect cation function have provided mixed results.^{3,4}
- **Objective:** The investigators of this study identified mutations in red blood cells of HS patients and used on-cell patch clamp analysis to determine how those mutations affect activity of cation channels in red blood cells.

Methods

- DNA and RNA were isolated from whole-blood specimens of 13 patients with a clinical diagnosis of HS.
- cDNA was generated from the isolated mRNA for Sanger sequencing of SLC4A1.
- When an *SLC4A1* mutation was not detected, Sanger sequencing of *ANK1* and *SPTB* was performed on cDNA and/or genomic DNA (gDNA).
- Whole-exome sequencing (WES) was conducted on gDNA from blood specimens (n=6) that had been uninformative in the other mutational analyses.
 Sanger sequencing was used to confirm any mutations detected by WES.
- On-cell patch clamp analysis was conducted on a subset of red cells from HS patients who had mutations identified; non-HS red cells were also analyzed as controls.

Results

- Among 13 patients with a clinical diagnosis of HS
 - 5 had previously identified pathogenic variants in SLC4A1 (2 of 5 were siblings)
 - 7 had novel pathogenic variants identified in SLC4A1 (1), ANK1 (2), or SPTB (2)
 - 1 patient with a novel *ANK1* mutation also had a novel missense variant with suspected pathogenicity identified in *SPTA1*.
 - 1 had a novel likely pathogenic variant in SPTB
- Red blood cells from 6 HS patients with identified mutations (*SLC4A1*, *ANK1*, and *SPTB*) were used for on-cell patch clamp analysis. Cells from these patients had substantial cation channel activity (average unitary conductance of cation channels, 26+2.1 pS).
- The mechanosensitive cation channel inhibitor *Grammastola spatulata* mechanotoxin-4 almost completely blocked the increased cation channel activity; this and the above results are consistent with modulation a specific ion channel, PIEZO1, causing the channel activity.

Conclusions

- The findings of this study confirm that patients with variants that cause HS have increased cation channel activity.
- The increased activity may be largely caused by modulating PIEZO1.

Article published in *Haematologica*

Authors

David H Vandorpe,¹ Boris E Shmukler,¹ Yann Ilboudo,² Swati Bhasin,¹ Beena Thomas,¹ Alicia Rivera,¹ Jay G Wohlgemuth,³ Jeffrey S Dlott,³ L Michael Snyder,³ Colin Sieff,⁴ Manoj Bhasin,¹ Guillaume Lettre,² Carlo Brugnara,⁵ Seth L Alper¹

Affiliations

¹Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, MA, USA ²Montreal Heart Institute and Université de Montréal, Montréal, Québec, Canada ³Quest Diagnostics, Secaucus, NJ, USA ⁴Dana-Farber Cancer Center and Boston Children's Hospital and Harvard Medical School, Boston, MA, USA ⁵Harvard Medical School, Boston, MA, USA

Citation

Vandorpe DH, Shmukler BE, Ilboudo Y, et al. *Haematogica*. 2021 Jun 10. doi:10.3324/haematol.2021.278770

Webpage

https://pubmed.ncbi.nlm.nih.gov/34 109777/

References

- 1. He B-J, Deng Z-F, Tao Y-F, et al. *Acta Haematol.* 2018;139:60-66.
- 2. Zarkowsky HS, Oski FA, Sha'afi R et al. *N Engl J Med.* 1968;278:573-581.
- 3. Hertz L, Huisjes R, Llaudet-Planas, E, et al. *Front Physiol.* 2017;8:673.
- 4. Petkova-Kirova P, Hertz L, Danielczok J, et al. *Front Physiol*. 2019;10:386.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2021 Quest Diagnostics Incorporated. All rights reserved. KS10309 6/2021.